Home » Economy » Pharma – AstraZeneca is hoping for lung cancer resources News

Pharma – AstraZeneca is hoping for lung cancer resources News

Saturday, September 9th, 2017 | Economy

A broad-based clinical trial with immunotherapy Imfinzi against certain forms of lung cancer had provided encouraging results, the British Pharmacist said. Patients treated with infusion were therefore on average 11 months longer than patients who received a placebo. AstraZeneca CEO Pascal Soriot said on Saturday at an oncologist congress in Madrid, according to experts, the drug could replace conventional treatment methods.
Soriot explained that the therapy with Imfinzi was designed for an early stage of lung cancer. Thus his group is differentiated from the competition, which has recently made more progress in the treatment of advanced tumors. In the early approach, the company sees a great opportunity for AstraZeneca. Finally, more and more people are likely to be diagnosed with lung cancer at an early stage, according to Soriot.
AstraZeneca had recently suffered a heavy defeat in drug development. The result of a large study indicated that a certain immune therapy can not help lung cancer patients. According to estimates by analysts, the company, which has now been successfully tested, would be able to earn annual revenues of around two billion dollars. According to the experts, the British have a two to three-year lead over their rivals.


Participations - Ebner advocates the dec

Martin Ebner and his wife have increased their share of Myriad to more

Video surveillance: field trial with fac

We see and recognize you: On Tuesday, a field trial for facial recognition

+++ Stock ticker +++ - Swiss stock marke

13:12 In anticipation of a shrinking oversupply, investors were exposed to crude oil

Apple and Accenture close partnership fo

Apple and Accenture make common thing. The two companies have announced plans to